Sickness absence triggers and reasonable adjustments
Managing sickness absence can be a tricky area, particularly in the case of disabled employees, who may require more time off than others.
The application, without modification, of an employer’s sickness absence policy to a disabled employee may give rise to a discrimination claim.
Under section 20 of the Equality Act, where a provision, criterion or practice (PCP) puts a disabled employee at a substantial disadvantage compared with employees who are not disabled, the employer is required to make such adjustments as are reasonable to remove that disadvantage. What is reasonable will depend on all the circumstances of the case…
Click on the link below to read the rest of the Wragge Lawrence Graham & Co briefing.
Sign in or Register to continue reading this article
It's quick, easy and free!
It takes just 5 minutes to register. Answer a few simple questions and once completed you’ll have instant access.Register now
Why register to The Lawyer
In-depth, expert analysis into the stories behind the headlines from our leading team of journalists.
Identify the major players and business opportunities within a particular region through our series of free, special reports.
Receive your pick of The Lawyer's daily and weekly email newsletters, tailored by practice area, region and job function.
More relevant to you
To continue providing the best analysis, insight and news across the legal market we are collecting some information about who you are, what you do and where you work to improve The Lawyer and make it more relevant to you.
News from Wragge Lawrence Graham & Co
News from The Lawyer
Briefings from Wragge Lawrence Graham & Co
Wragge Lawrence Graham & Co’s finance litigation experts bring you the latest on the cases and issues affecting the lending industry.
Eli Lilly succeeds in overturning award of DNIs regarding UK, FR, IT and ES designations of its European patent
The Court of Appeal has delivered its long-awaited judgment in the Actavis v Eli Lillydispute, ruling that Actavis is not entitled to a declaration of noninfringement (DNI) of Eli Lilly’s European patent.